The outbreak of the COVID-19 pandemic prompted a reevaluation of healthcare regulations, particularly with regard to telemedicine and the prescription of controlled medications. One significant development in this area is the temporary exceptions granted by the Drug Enforcement Administration (DEA) to the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which governs the prescription of controlled substances.
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008, commonly known as the Ryan Haight Act, set stringent guidelines for prescribing controlled medications. Under this act, prescribing practitioners were required to conduct in-person evaluations of patients before prescribing these medications, with some limited exceptions. This law was enacted to combat the proliferation of online pharmacies that were distributing controlled substances without proper medical oversight.
In January 2020, the Secretary of the Department of Health and Human Services (HHS) declared the COVID-19 Public Health Emergency (COVID-19 PHE). In response to this unprecedented global crisis, the DEA recognized the need for flexibility in healthcare practices. Under the authority of the Public Health Service Act, the DEA granted temporary exceptions to the Ryan Haight Act and its implementing regulations to accommodate the surge in telemedicine during the COVID-19 PHE by suspending the requirement for in-person evaluations of patients before prescribing controlled medications.
On March 1, 2023, the DEA and HHS introduced two Notices of Proposed Rulemakings (NPRMs) to solicit public input on allowing the prescription of controlled medications via telemedicine, even when an in-person evaluation hadn’t taken place. Following public feedback, the DEA and HHS issued the First Temporary Rule on May 10, 2023, extending the exceptions to existing DEA regulations, preventing lapses in care for patients, and applying particularly to practitioner-patient relationships formed after the expiration of the COVID-19 Public Health Emergency on May 11, 2023. These extensions lasted until November 11, 2023.
As the healthcare landscape continues to evolve and with a strong emphasis on the role of telemedicine, the DEA and HHS are taking measured steps to address these changes. Building on the feedback and insights gathered through Telemedicine Listening Sessions, these regulatory bodies have introduced a second temporary rule. In this latest development, the DEA and HHS are further extending exceptions to existing DEA regulations for new practitioner-patient relationships through December 31, 2024.
As we move forward, it’s essential for healthcare practitioners, policymakers and the public to stay informed about these developments and actively participate in discussions surrounding the future of telemedicine and the prescription of controlled medications.
As a boutique law firm dedicated to supporting the healthcare community, the firm’s goal is to ensure clients are protected. Please contact the Florida Healthcare Law Firm to set up a consultation today.